There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Outlook Therapeutics (OTLK – Research Report), BioNano Genomics (BNGO – Research Report) and Ayr Wellness (AYRWF – Research Report) with bullish sentiments.
Outlook Therapeutics (OTLK)
BTIG analyst Julian Harrison reiterated a Buy rating on Outlook Therapeutics on March 9 and set a price target of $7.00. The company’s shares closed last Monday at $1.04.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
Currently, the analyst consensus on Outlook Therapeutics is a Strong Buy with an average price target of $5.33.
See the top stocks recommended by analysts >>
BioNano Genomics (BNGO)
BTIG analyst Mark Massaro reiterated a Buy rating on BioNano Genomics on March 10 and set a price target of $3.00. The company’s shares closed last Monday at $1.26, close to its 52-week low of $1.16.
According to TipRanks.com, Massaro ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
BioNano Genomics has an analyst consensus of Strong Buy, with a price target consensus of $5.50, implying a 366.1% upside from current levels. In a report issued on March 6, Maxim Group also assigned a Buy rating to the stock with a $6.00 price target.
Ayr Wellness (AYRWF)
BTIG analyst Jonathan DeCourcey reiterated a Buy rating on Ayr Wellness on March 9 and set a price target of C$8.50. The company’s shares closed last Monday at $0.77.
According to TipRanks.com, DeCourcey is ranked 0 out of 5 stars with an average return of
Ayr Wellness has an analyst consensus of Moderate Buy, with a price target consensus of $3.65, a 405.8% upside from current levels. In a report issued on March 9, Needham also reiterated a Buy rating on the stock with a $3.75 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OTLK:
- Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
- BTIG biotechnology analyst to hold an analyst/industry conference call
- Outlook Therapeutics announces anticipated milestones
- Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
- Outlook sees cash runway through anticipated FDA approval of ONS-5010
